"Recent evidence indicates a potential therapeutic role of fluvoxamine for COVID-19," the statement reads.
The experiment of American scientists with fluvoxamine involved 741 people from 11 clinical centers in Brazil. Patients in the early stages of Covid-19 with a risk factor for severe disease (patients with diabetes, cardiovascular disease, lung disease, obesity, smoking, etc.) were admitted to the study.
It is noted that as a result of the study, of the 741 participants taking the antidepressant fluvoxamine, only 75 required hospitalization. In seven days of the experiment, 40 people recovered from the coronavirus.
Fluvoxamine is a synthetic drug that belongs to the group of selective serotonin reuptake inhibitors. Used for depression of various origins and obsessive-compulsive disorders.